Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares to Pay Quarterly Dividend of $0.94

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) declared a quarterly dividend on Monday, November 2nd. Investors of record on Friday, November 20th will be given a dividend of $0.94 per share by the biopharmaceutical company on Thursday, December 3rd. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th.

Regeneron Pharmaceuticals has a payout ratio of 9.6% indicating that its dividend is sufficiently covered by earnings. Analysts expect Regeneron Pharmaceuticals to earn $53.12 per share next year, which means the company should continue to be able to cover its $3.76 annual dividend with an expected future payout ratio of 7.1%.

Regeneron Pharmaceuticals Stock Up 3.6%

NASDAQ:REGN traded up $33.37 during trading hours on Monday, reaching $961.26. The company’s stock had a trading volume of 1,656,990 shares, compared to its average volume of 826,516. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66. The company has a market cap of $98.97 billion, a price-to-earnings ratio of 21.22, a price-to-earnings-growth ratio of 1.57 and a beta of 0.10. Regeneron Pharmaceuticals has a one year low of $591.52 and a one year high of $974.00. The business’s 50-day moving average is $793.30 and its 200-day moving average is $738.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. During the same quarter in the prior year, the company posted $11.83 EPS. The firm’s revenue was up 36.3% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals will post 49.10 EPS for the current year.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong Q3 results drove the bullish reaction. Regeneron beat expectations with adjusted earnings per share of $20.07 versus the $16.51 consensus, while revenue rose 36.3% year over year to $5.12 billion. The results reflected stronger Sanofi profit sharing and continued momentum for key products including Dupixent. Analysts Raise Their Forecasts on Regeneron After Upbeat Q3 Results
• Positive Sentiment: Analysts broadly raised their targets. Guggenheim lifted its target to $1,100 and maintained a buy rating, while JPMorgan raised its target to $1,050 with an overweight rating. Bank of America increased its target to $1,030 and Truist raised its target to $982, also maintaining bullish ratings. Cantor Fitzgerald, Leerink Partners and other firms also raised their targets, with some forecasts reaching as high as $1,175. Top Analyst Forecasts for Regeneron
• Positive Sentiment: Pipeline and strategic developments add support. Investors are also responding to stronger Libtayo data in high-risk skin cancer and an expanded BARDA supply agreement for Ebola treatment, alongside ongoing share repurchases and a deep development pipeline. Why Regeneron Shares Are in Focus After Strong Earnings
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share. The dividend is scheduled for payment on December 3 to shareholders of record November 20, providing a modest income component with an annualized yield of approximately 0.4%.
• Negative Sentiment: Several analysts remain cautious at the elevated valuation. Bernstein, Morgan Stanley, RBC, Wells Fargo and Baird raised their targets but retained market perform, equal-weight, sector-perform or neutral ratings. Their targets remain below the current trading level, signaling concern that much of the improved earnings outlook may already be reflected in REGN’s price.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.